Cancer Patents (Class 514/19.3)
  • Patent number: 10383931
    Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 20, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
  • Patent number: 10364270
    Abstract: Disclosed is related to a synthetic peptide consisting of an amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1). Also provided are a pharmaceutical composition benefic to eye care or eye health comprising the peptide, and a method for wound healing using the peptide.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 30, 2019
    Assignee: PRO SUNFUN BIOTECH RESEARCH AND DEVELOPMMENT CO., LTD.
    Inventors: Min-Chuan Huang, Syue-Ting Chen, Yu-Chun Liu
  • Patent number: 10357538
    Abstract: The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 23, 2019
    Assignee: NORTHERN SYDNEY LOCAL HEALTH DISTRICT
    Inventors: Ross Arthur Davey, Christopher John Weir
  • Patent number: 10350260
    Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: July 16, 2019
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: 10350262
    Abstract: The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. In some aspects the invention includes contacting a cancer cell with one or more exogenous methylation-controlled J protein (MCJ) agonist compounds to increase sensitivity of the cancer cell to one or more chemotherapeutic agents. In certain aspects the invention includes compounds and methods useful to kill cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 16, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Thomas Roberts, Tina Thornton
  • Patent number: 10344065
    Abstract: A method for treating Alzheimer's disease and a method for downregulating protein aggregation in brain are disclosed, which respectively comprises: administering a zinc finger-like peptide to a subject in need thereof, wherein the zinc finger-like peptide comprises an amino acid sequence of RRSSSCK (SEQ ID NO: 1).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 9, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Nan-Shan Chang, Yu-Min Kuo
  • Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10316077
    Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: June 11, 2019
    Assignee: Sapience Therapeutics, Inc.
    Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
  • Patent number: 10294276
    Abstract: The present invention describes a process for isolation of romidepsin from fermentation broth and preparation of crystals of romidepsin. The process of the invention includes fewer purification steps and provides romidepsin having purity of greater than 99.5% area by HPLC. The process of the invention involves simple purification steps and hence, does not require multiple chromatographic purification steps to achieve desired quality of romidepsin. The process is advantageous over reported processes in terms of 99.5% pure yield, fast process, less expensive and less cumbersome as multiple chromatographic purification is not necessary to achieve desired quality. The process for the preparation of crystals of romidepsin provides advantages like simple steps and involves use of single solvent. The process is advantageous in terms of time, cost, and simplicity.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: May 21, 2019
    Assignee: Concord Biotech Limited
    Inventors: Ankur S. Vaid, Anand M. Dhiman, Traunkant P. Sharma
  • Patent number: 10292992
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 21, 2019
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10293024
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 21, 2019
    Assignee: Blueberry Therapeutics Limited
    Inventor: John Ridden
  • Patent number: 10221417
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: March 5, 2019
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Jan Fiedler
  • Patent number: 10206975
    Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Swedish Orphan Biovitrum AB (PUBL)
    Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
  • Patent number: 10202456
    Abstract: Provided is a recombinant cell including inactivated pyruvate dehydrogenase kinase (PDK) gene, a composition for producing a polypeptide of interest including the recombinant cell, and a method of producing a polypeptide of interest using the recombinant cell.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 12, 2019
    Assignee: Samsung Bioepis Co., Ltd.
    Inventors: Eunyoung Park, Hye Young Suh, Hee Kyung Sung, Christina Yi, Sunkyu Kim
  • Patent number: 10196432
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: February 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventor: Jörn Dengiel
  • Patent number: 10189880
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: January 29, 2019
    Assignee: LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Mirjam H. M. Heemskerk, J. H. Frederik Falkenburg
  • Patent number: 10190174
    Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
  • Patent number: 10117946
    Abstract: The present invention relates to hydrogels comprising a first peptide with a covalently linked bioactive agent and optionally a second peptide. The present invention further relates to uses of the hydrogel for delivery of the bioactive agent or as an implant. The present invention further relates to drug delivery devices, implant, pharmaceutical or cosmetic compositions comprising the hydrogel. The present invention further relates to methods of local treatment of diseases and to methods for preparing the first peptide and the hydrogels.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: November 6, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Michael R. Reithofer, Charlotte A. E. Hauser, Kiat Hwa Chan, Archana Mishra
  • Patent number: 10087234
    Abstract: The invention relates to mimetic peptides of epitope(s) of Apolipoprotein A-I, diagnostic immunoassays comprising such mimetic peptides, as well as methods for diagnosing and methods for preventing and/or treating a cardiovascular disease.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 2, 2018
    Assignees: LES HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVE, HOFFMAN-LA ROCHE INC.
    Inventors: Nicolas Vuilleumier, Sabrina Pagano, Oliver Hartley, Hubert Gaertner, Priscila Camillo Teixeira, Paul Cutler, Philippe Ferber
  • Patent number: 10081810
    Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 25, 2018
    Assignees: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Qingguo Ruan, Youhai H. Chen, Tingting Fan, Yifan Ma, Lintao Cai, Shaowen Wang, Xiaochun Wan
  • Patent number: 10081654
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): (I) (VI) and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 25, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 10071154
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: September 11, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B Weiner, Matthew P Morrow
  • Patent number: 10072078
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: September 11, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
  • Patent number: 10064843
    Abstract: The present invention relates to a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a method of preparation thereof; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and health functional food for preventing or ameliorating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased because WJCPA-126 binds to CypA with high binding affinity exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: September 4, 2018
    Assignee: University-Industry Cooperation Group of Kyung Hee University
    Inventors: Sung Soo Kim, Won Jea Cho
  • Patent number: 10047138
    Abstract: Described herein are novel fusion proteins and nucleic acids encoding these fusion proteins. T cells into which such nucleic acids have been introduced are also contemplated. These T cells can express the fusion proteins on their cell surface. In various embodiments, these T cells can be used in assays to detect costimulatory ligands, inhibitors of costimulatory ligands, or inhibitors that can neutralize an inhibitor of a costimulatory ligand. Such assay methods are also described herein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AMGEN INC.
    Inventor: Christian Vettermann
  • Patent number: 10010541
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
  • Patent number: 9999655
    Abstract: Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Moerae Matrix, Inc.
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
  • Patent number: 9980956
    Abstract: Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 29, 2018
    Assignees: 3M INNOVATIVE PROPERTIES COMPANY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John Vasilakos, Willem Overwijk
  • Patent number: 9975885
    Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 22, 2018
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Sarah Emma St. John, Andrew D. Mesecar
  • Patent number: 9962425
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 8, 2018
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Patent number: 9962424
    Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: May 8, 2018
    Assignee: LANTMÄNNEN AS-FAKTOR AB
    Inventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
  • Patent number: 9957292
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 1, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Patent number: 9944975
    Abstract: Disclosed herein are hybridization buffer compositions and hybridization compositions, methods of making the compositions, and methods of using the compositions, such as the hybridization of DNA or RNA sequences by fluorescence in situ hybridization (“FISH”) and blot hybridization methodologies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: April 17, 2018
    Assignee: Abbott Molecular Inc.
    Inventor: Kimberly A. Wilber-Mader
  • Patent number: 9944918
    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 17, 2018
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 9932386
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: April 3, 2018
    Assignee: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
  • Patent number: 9895423
    Abstract: Stabilized pharmaceutical formulations of insulin aspart are disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Patent number: 9891231
    Abstract: The invention provides, in part, methods for diagnosing a pancreatic ?-cell disorder, predicting a subject's risk of developing a pancreatic ?-cell disorder, monitoring pancreatic ?-cell function or pancreatic ?-cell mass in a subject at risk of developing a pancreatic ?-cell disorder, monitoring efficacy of a treatment of a pancreatic ?-cell disorder in a subject, identifying a subject having an increased risk of developing a pancreatic ?-cell disorder, selecting a subject for treatment of a pancreatic ?-cell disorder, selecting a subject for participation in a clinical study, and detecting endoplasmic reticulum stress in a pancreatic ?-cell. These methods include determining at least one level of soluble mesencephalic astrocyte-derived neurotrophic factor (MANF) in a biological sample from the subject. Also provided are pharmaceutical compositions containing a soluble MANF protein and kits containing an antibody or an antigen-binding antibod fragment that binds specifically to a soluble MANF.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: February 13, 2018
    Assignee: University of Massachusetts
    Inventors: Fumihiko Urano, Kohsuke Kanekura
  • Patent number: 9879081
    Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 30, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hye Young Suh, Jae Il Lee, Su-Jeong Hwang
  • Patent number: 9873726
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 23, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Patent number: 9796757
    Abstract: A peptide, derivative or peptidomimetic that blocks binding of GNA12 to ?SNAP is provided as are methods of using the same to inhibit thrombin-induced von Willebrand Factor secretion and prevent or treat thrombosis.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: October 24, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Richard D. Minshall, Luiza Rusu
  • Patent number: 9783585
    Abstract: The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably linked to the N-terminal end of the protein of interest. The nucleic acid sequence encoding the sequence tag and the protein comprise part of an expression vector. The protein is expressed with the N-terminal sequence tag. In certain embodiments, the sequences of the present invention can be used with one or more chaperone or accessory proteins. In particular embodiments, the one or more chaperone/accessory proteins are encoded by the same vector or separate vectors.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 10, 2017
    Assignee: JOHNS HOPKINS UNIVERSITY
    Inventors: Jennifer Pluznick, Niranjana Natarajan, Blythe Shepard
  • Patent number: 9758835
    Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 12, 2017
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
  • Patent number: 9732158
    Abstract: The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: August 15, 2017
    Assignee: NMDX, LLC
    Inventor: Patrick J. Muraca
  • Patent number: 9644185
    Abstract: A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed. According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: May 9, 2017
    Assignees: SNU R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Yoon Jeong Park, Gene Lee, Hyun Nam, Jin Sook Suh, Chong-Pyoung Chung, Jue-Yeon Lee
  • Patent number: 9637518
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: May 2, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, Liping Zhang, Erik M. Stang
  • Patent number: 9574012
    Abstract: Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: February 21, 2017
    Assignees: Sanofi (China) Investment Co., Ltd. Shanghai Branch, Shanghai Jiao Tong University
    Inventors: Dawei Li, Zhenghua Wu, Hao Guo, Qi Zhu, Dhahiri S. Mashausi
  • Patent number: 9567566
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: February 14, 2017
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin
  • Patent number: 9561265
    Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: February 7, 2017
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 9555126
    Abstract: An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: January 31, 2017
    Assignee: Sanofi
    Inventor: Rodica Morariu